1. Home
  2. FATE vs PLBY Comparison

FATE vs PLBY Comparison

Compare FATE & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • PLBY
  • Stock Information
  • Founded
  • FATE 2007
  • PLBY 1953
  • Country
  • FATE United States
  • PLBY United States
  • Employees
  • FATE N/A
  • PLBY N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • PLBY Recreational Games/Products/Toys
  • Sector
  • FATE Health Care
  • PLBY Consumer Discretionary
  • Exchange
  • FATE Nasdaq
  • PLBY Nasdaq
  • Market Cap
  • FATE 108.2M
  • PLBY 113.4M
  • IPO Year
  • FATE 2013
  • PLBY N/A
  • Fundamental
  • Price
  • FATE $0.77
  • PLBY $1.12
  • Analyst Decision
  • FATE Hold
  • PLBY Buy
  • Analyst Count
  • FATE 9
  • PLBY 2
  • Target Price
  • FATE $5.50
  • PLBY $2.35
  • AVG Volume (30 Days)
  • FATE 1.6M
  • PLBY 605.1K
  • Earning Date
  • FATE 03-05-2025
  • PLBY 03-13-2025
  • Dividend Yield
  • FATE N/A
  • PLBY N/A
  • EPS Growth
  • FATE N/A
  • PLBY N/A
  • EPS
  • FATE N/A
  • PLBY N/A
  • Revenue
  • FATE $13,631,000.00
  • PLBY $116,135,000.00
  • Revenue This Year
  • FATE N/A
  • PLBY N/A
  • Revenue Next Year
  • FATE N/A
  • PLBY $3.28
  • P/E Ratio
  • FATE N/A
  • PLBY N/A
  • Revenue Growth
  • FATE N/A
  • PLBY N/A
  • 52 Week Low
  • FATE $0.74
  • PLBY $0.52
  • 52 Week High
  • FATE $7.35
  • PLBY $2.44
  • Technical
  • Relative Strength Index (RSI)
  • FATE 33.08
  • PLBY 38.30
  • Support Level
  • FATE $0.83
  • PLBY $1.02
  • Resistance Level
  • FATE $0.96
  • PLBY $1.16
  • Average True Range (ATR)
  • FATE 0.06
  • PLBY 0.11
  • MACD
  • FATE -0.00
  • PLBY 0.01
  • Stochastic Oscillator
  • FATE 11.54
  • PLBY 36.84

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About PLBY PLBY Group Inc.

PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

Share on Social Networks: